Edetic Acid
drug drugOn this page
Also known as Acide edetiqueAcido edeticoEdtaEthylenebis(iminodiacetic acid)Versene acidethylenediaminetetraacetic acidEthylene diamine tetra-acetic acidSID29215444SID26754509TRISODIUM ETHYLENEDIAMINE TETRACETATESID144209934Ethylenediamine tetraacetic acidETHYLENEDIAMINE TETRACETIC ACIDEdetic_acidÊETHYLENEDIAMINE TETRACETIC_acidEdetic_acidÂ
Summary
Edetic Acid (CHEMBL858) is an approved small-molecule copper chelator; indicated across 4 conditions including coronary artery disorder and urinary tract infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 4 conditions
- Clinical trials: 12
- Chemistry: 292.24 Da · C10H16N2O8
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL858 |
| Name | Edetic Acid |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 6049 |
| ChEBI | CHEBI:4735 |
| Molecular formula | C10H16N2O8 |
| Molecular weight | 292.24 |
| InChIKey | KCXVZYZYPLLWCC-UHFFFAOYSA-N |
SMILES: C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O
IUPAC name: 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid
Pharmacological roles (ChEBI): antidote, geroprotector, copper chelator, anticoagulant, calcium chelator.
Also known as: Acide edetique, Acido edetico, Edetic acid, Edta, Ethylenebis(iminodiacetic acid), Versene acid, edta, ethylenediaminetetraacetic acid, Ethylenediaminetetraacetic acid, Ethylene diamine tetra-acetic acid, SID29215444, SID26754509
Patent coverage: 419,539 distinct patent families (1,231,124 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,231,119 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Protein phosphatase EYA2, Angiotensin-converting enzyme, Amyloid-beta precursor protein, Metallo-beta-lactamase type 2.
Bioactivity
ChEMBL activities: 3 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| C7C422 | 6.4 | IC50 | 400 | nM | CHEMBL_ACT_29305797 |
| TDP1 | 5.9 | Potency | 1259 | nM | CHEMBL_ACT_3926813 |
| APP | 5.11 | IC50 | 7700 | nM | CHEMBL_ACT_13448988 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| urinary tract infection | 3 | MONDO:0100338 | EFO:0003103 |
| herpes simplex infectious disease | 2 | MONDO:0004609 | EFO:1002022 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 12.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE4 | 2 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00294502 | PHASE4 | COMPLETED | Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia |
| NCT03419429 | PHASE4 | COMPLETED | Simvastatin Gel With Perforated Resorbable Membranes in Treatment of Intrabony Defects in Chronic Periodontitis |
| NCT00044213 | PHASE3 | COMPLETED | Trial to Assess Chelation Therapy (TACT) |
| NCT03853200 | PHASE2/PHASE3 | COMPLETED | Comparison of Antibacterial Efficacy of Three Final Irrigants |
| NCT02286258 | PHASE1/PHASE2 | TERMINATED | Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR) |
| NCT04893577 | PHASE2 | COMPLETED | EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions |
| NCT07116252 | Not specified | ACTIVE_NOT_RECRUITING | Effect of Different Irrigation Protocols on Postoperative Endodontic Pain and Inflammation |
| NCT02714075 | Not specified | COMPLETED | Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Zinc, Citric Acid/Trisodium Citrate and EDTA |
| NCT03253393 | Not specified | COMPLETED | Smart Touch Non-dispensing Handling Studies |
| NCT03336970 | Not specified | COMPLETED | Efficacy of Chlorhexidine as a Final Irrigant in Single-visit Root Canal Treatment |
| NCT04310254 | Not specified | COMPLETED | Effect of Different Final Irrigation Protocols on Postoperative Endodontic Pain in Devital Teeth |
| NCT04980066 | Not specified | UNKNOWN | Evaluation of Sticky Bone With or Without EDTA for Treatment of Gingival Recession |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: coronary artery disorder, urinary tract infection, herpes simplex infectious disease